TAKEDA PHARMS USA Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TAKEDA PHARMS USA, and what generic alternatives to TAKEDA PHARMS USA drugs are available?
TAKEDA PHARMS USA has forty approved drugs.
There are one hundred and six US patents protecting TAKEDA PHARMS USA drugs.
There are one thousand four hundred and thirty patent family members on TAKEDA PHARMS USA drugs in fifty-nine countries and one hundred and eighty-eight supplementary protection certificates in nineteen countries.
Summary for TAKEDA PHARMS USA
International Patents: | 1430 |
US Patents: | 106 |
Tradenames: | 43 |
Ingredients: | 33 |
NDAs: | 40 |
Drugs and US Patents for TAKEDA PHARMS USA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | NINLARO | ixazomib citrate | CAPSULE;ORAL | 208462-003 | Nov 20, 2015 | RX | Yes | Yes | 7,687,662 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Takeda Pharms Usa | DUETACT | glimepiride; pioglitazone hydrochloride | TABLET;ORAL | 021925-001 | Jul 28, 2006 | AB | RX | Yes | Yes | 8,071,130 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Takeda Pharms Usa | OSENI | alogliptin benzoate; pioglitazone hydrochloride | TABLET;ORAL | 022426-004 | Jan 25, 2013 | DISCN | Yes | No | 7,807,689 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Takeda Pharms Usa | VYVANSE | lisdexamfetamine dimesylate | CAPSULE;ORAL | 021977-001 | Feb 23, 2007 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | LIVTENCITY | maribavir | TABLET;ORAL | 215596-001 | Nov 23, 2021 | RX | Yes | Yes | 11,684,632 | ⤷ Sign Up | ⤷ Sign Up | ||||
Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | 9,125,909*PED | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TAKEDA PHARMS USA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-002 | Jan 30, 2009 | 9,145,389 | ⤷ Sign Up |
Takeda Pharms Usa | ACTOS | pioglitazone hydrochloride | TABLET;ORAL | 021073-002 | Jul 15, 1999 | 6,211,205 | ⤷ Sign Up |
Takeda Pharms Usa | OSENI | alogliptin benzoate; pioglitazone hydrochloride | TABLET;ORAL | 022426-002 | Jan 25, 2013 | 6,211,205 | ⤷ Sign Up |
Takeda Pharms Usa | ULORIC | febuxostat | TABLET;ORAL | 021856-001 | Feb 13, 2009 | 5,614,520 | ⤷ Sign Up |
Takeda Pharms Usa | OSENI | alogliptin benzoate; pioglitazone hydrochloride | TABLET;ORAL | 022426-005 | Jan 25, 2013 | 6,172,090 | ⤷ Sign Up |
Takeda Pharms Usa | PREVACID | lansoprazole | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | 021428-002 | Aug 30, 2002 | 5,013,743*PED | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TAKEDA PHARMS USA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | For Injection | 3.5 mg/vial | ➤ Subscribe | 2008-11-20 |
➤ Subscribe | Chewable Tablet | 500 mg, 750 mg and 1000 mg | ➤ Subscribe | 2008-10-27 |
➤ Subscribe | Delayed-release Tablets | 1.2 g | ➤ Subscribe | 2009-12-16 |
➤ Subscribe | Extended-release Tablets | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2009-12-29 |
➤ Subscribe | Tablets | 0.6 mg | ➤ Subscribe | 2011-12-23 |
➤ Subscribe | Delayed-release Orally Disinte | 15 mg and 30 mg | ➤ Subscribe | 2006-12-27 |
➤ Subscribe | Tablets | 12.5 mg/500 mg and 12.5 mg/1000 mg | ➤ Subscribe | 2017-01-25 |
➤ Subscribe | Delayed-release Capsule | 30 mg | ➤ Subscribe | 2010-11-30 |
➤ Subscribe | Tablets | 8 mg | ➤ Subscribe | 2009-07-22 |
➤ Subscribe | Extended-release Capsules | 37.5 mg and50 mg | ➤ Subscribe | 2017-08-03 |
➤ Subscribe | Tablets | 40 mg and 80 mg | ➤ Subscribe | 2013-02-13 |
➤ Subscribe | Capsules | 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg | ➤ Subscribe | 2011-02-23 |
➤ Subscribe | Injection | 10 mg/mL | ➤ Subscribe | 2015-08-25 |
➤ Subscribe | Oral Powder | 750 mg and 1000 mg | ➤ Subscribe | 2015-11-25 |
➤ Subscribe | Extended-release Tablets | 15 mg/1000 mg and 30 mg/1000 mg | ➤ Subscribe | 2011-09-23 |
➤ Subscribe | Tablets | 15 mg/500 mg and 15 mg/850 mg | ➤ Subscribe | 2008-03-06 |
➤ Subscribe | Delayed-release Pellets/Capsul | 15 mg and 30 mg | ➤ Subscribe | 2005-12-05 |
➤ Subscribe | Tablets | 30 mg/2 mg and 30 mg/4 mg | ➤ Subscribe | 2009-12-22 |
➤ Subscribe | Capsule | 60 mg | ➤ Subscribe | 2010-08-25 |
➤ Subscribe | Tablets | 6.25 mg, 12.5 mg and 25 mg | ➤ Subscribe | 2017-01-25 |
➤ Subscribe | Extended-release Capsules | 100 mg and 200 mg | ➤ Subscribe | 2006-02-02 |
➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mgand 20 mg | ➤ Subscribe | 2017-10-02 |
➤ Subscribe | Extended-release Capsules | 12.5 mg and 25 mg | ➤ Subscribe | 2017-08-07 |
International Patents for TAKEDA PHARMS USA Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2705681 | ⤷ Sign Up |
Norway | 2300013 | ⤷ Sign Up |
Japan | 5763609 | ⤷ Sign Up |
South Africa | 200602056 | ⤷ Sign Up |
Japan | 2019065019 | ⤷ Sign Up |
Taiwan | I718105 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for TAKEDA PHARMS USA Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1586571 | 92374 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: ALOGLIPTIN SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE. FIRST REGISTRATION: 20130923 |
1506211 | CR 2014 00037 | Denmark | ⤷ Sign Up | PRODUCT NAME: ET KOMBINATIONSPRODUKT AF DAPAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER DAPAGLIFLOZINPROPANDIOLMONOHYDRAT OG METFORMIN ELLER SALTE DERAF, HERUNDER METFORMINHYDROCHLORID; REG. NO/DATE: EU/1/13/900 20140116 |
1261586 | 15/2012 | Austria | ⤷ Sign Up | PRODUCT NAME: KOMBINATIONSPRODUKT VON SAXAGLIPTIN UND METFORMIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON, BEINHALTEND DIE HYDROCHLORIDSALZE VON SAXAGLIPTIN UND METFORMIN; REGISTRATION NO/DATE: EU/1/11/731/001-EU/1/11/731/012 20111124 |
2178888 | CA 2017 00014 | Denmark | ⤷ Sign Up | PRODUCT NAME: IXAZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER IXAZOMIBCITRAT; REG. NO/DATE: EU/1/16/1094 20161123 |
2300013 | 19C1033 | France | ⤷ Sign Up | PRODUCT NAME: BRIGATINIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/18/1264 20181126 |
0193256 | SPC/GB01/016 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE HYDROCHLORIDE SALT; REGISTERED: CH IKS 55 378 01 20000927; CH IKS 55 378 02 20000927; CH IKS 55 378 03 20000927; UK EU/1/00/151/001 20001011; UK EU/1/00/151/002 20001011; UK EU/1/00/151/003 20001011; UK EU/1/00/151/004 20001011; UK EU/1/00/151/005 20001011; UK EU/1/00/151/006 20001011 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.